Leadership & Pay ·
PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 data and board additions
PDSBPDS Biotechnology Corp
On October 20, 2026, PDS Biotechnology Corporation filed a Form 8-K to update its corporate presentation deck. The filing incorporates Exhibit 99.1, which details the company's oncology drug development programs, including clinical results for PDS0301 and PDS0101. The presentation notes that Dr. Patrick Soon-Shiong joined the Board of Directors following a September 2026 financing led by Nant Capital. It also outlines near-term catalysts with five data readouts anticipated between Q4 2026 and Q2 2028 across various indications including prostate cancer, colorectal cancer, and Kaposi sarcoma. PDS Biotechnology Corporation operates in the biotechnology industry, focusing on developing immunotherapies for solid tumors.